4d Molecular Therapeutics, Inc. · NASDAQ:FDMT

4d Molecular Therapeutics — Technical Presentation (July 2025)

12 slides from 4d Molecular Therapeutics's technical presentation, July 2025

  1. Slide 1: Interim Results from the SPECTRA Phase 2a Clinical Trial of 4D-150 in DME

    Interim Results from the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Diabetic Macular Edema David Almeida, MD, MBA, PhD Erie Retina Research, Erie, PA On behalf of the SPECTRA investigators

  2. Slide 2: Disclosures

    Disclosures Research Support & Grants Alcon, Allergan/Abbvie, ANI Pharmaceuticals, Boehringer Ingelheim, Eyepoint, Genentech, Novartis, Oculis, Regeneron, Roche Consulting & Advisory Roles Allergan/Abbvie, ANI Pharmaceuticals, Boehringer Ingelheim, Genentech, Oculis, Regeneron, Unity Biotechnology S

  3. Slide 3: 4D-150: Proprietary Capsid Carrying a Dual-Transgene Payload

    4D-150: Proprietary Capsid Carrying a Dual-Transgene Payload R100 AAV Capsid 4D-150 VEGF-C RNAi Aflibercept DNA RNA (VEGF Trap) transcription Capsid base Peptide insertions Protein Point mutations (internal) translation PIGF VEGF-A VEGF-B R100 capsid designed for: VEGF-C Selective tropism for retina

  4. Slide 4: SPECTRA Enrolled DME Patients with Focus on Safety & Dose Selection

    SPECTRA Enrolled DME Patients with Focus on Safety & Dose Selection Diagnosis within 2 years, CST ≥350 μm (includes treatment naïve) Key Eligibility Criteria Confirmed anti-VEGF response (CST decrease ≥40 μm at Week –1 versus Week –8) o Assessed by SD-OCT and confirmed by independent reading center.

  5. Slide 5: 4D-150 Continues to be Well Tolerated Through 60 Weeks with No Intraocular Inflammation

    4D-150 Continues to be Well Tolerated Through 60 Weeks with No Intraocular Inflammation at any Timepoint at any Dose Level Anterior Chamber Cells Vitreous Cells Topical Corticosteroid NEI/SUN Score 0 (none) 1+ 2+ Phase 3 3+ Dose: 4+ 3E10 vg/eye MV Missed Visit (N=9) ▪ All patients completed the 16-

  6. Slide 6: Mean IOP Within Normal Limits

    Mean IOP Within Normal Limits No IOP <6 mmHg at any visit Phase 3 Dose: 3E10 vg/eye (N=9) Lower Doses: 1E10 vg/eye (N=12) and 5E9 vg/eye (N=1) Topical Topical Corticosteroid Corticosteroid 30 30 Study Eye Study Eye 25 Contralateral Eye 25 Contralateral Eye IOP (±SD) in mm Hg IOP (±SD) in mm Hg 20 20

  7. Slide 7: Sustained Gains in Visual Acuity

    Sustained Gains in Visual Acuity Through Week 60 4D-150 Aflibercept Phase 3 Dose, 3E10 vg/eye (n=9) 25 Lower Doses (1E10 & 5E9 vg/eye) (n=11†) Mean ±SD Change in BCVA 20 (ETDRS letters) 15 +9.2 +9.7 10 +6.4 +8.3 5 0 -5 -10 -8 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 Weeks †2 subjects missed >

  8. Slide 8: Sustained Improvement in Anatomic Control

    Sustained Improvement in Anatomic Control Through Week 60 4D-150 Aflibercept Phase 3 Dose, 3E10 vg/eye (n=9) 50 Lower Doses (1E10 & 5E9 vg/eye) (n=11†) 0 Mean ±SD Change -50 in CST (µm) -100 –131* –140 -150 –140 –174 -200 -250 -300 -350 -8 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 Weeks *One s

  9. Slide 9: Strong Treatment Burden Reduction and Dose Response vs. Lower Doses

    4D-150 3E10 vg/eye: Strong Treatment Burden Reduction and Dose Response vs. Lower Doses Through Week 60 8 Phase 3 Dose (n=9) Loading Phase Phase 3 Dose, 3E10 vg/eye (n=9) >2 7 Mean Cumulative Number of Injections injections 2 0 Lower Doses (1E10 & 5E9 vg/eye) (n=11†) 4* injections 6 2 2 5 injections

  10. Slide 10: Strong Treatment Burden Reduction vs. Projected Aflibercept Q8W

    4D-150 3E10 vg/eye: Strong Treatment Burden Reduction and Dose Response vs. Lower Doses Through Week 60 8 Loading Phase Phase 3 Dose, 3E10 vg/eye (n=9) 7 7 Mean Cumulative Number of Injections Projected aflibercept Q8W 6 6 (Weeks 8-60) Phase 3 Dose (n=9) 5 4 >2 injections 2 0 3 4* injections 78% red

  11. Slide 11: SPECTRA Conclusions Through Week 60

    SPECTRA Conclusions Through Week 60 Safety Data Efficacy Data (Phase 3 Dose) ▪ No intraocular inflammation (No SUN/NEI score ▪ Sustained vision gains >0) observed at any timepoint or dose level ▪ Sustained anatomic control ▪ No hypotony, endophthalmitis, vasculitis, choroidal ▪ Supplemental injectio

  12. Slide 12: Thank you to all trial investigators, research staff, patients, and caregivers

    Thank you to all trial investigators, research staff, patients, and caregivers who contributed to this work SPECTRA Investigators Neal Palejwala David A. Eichenbaum Fuad Makkouk Allen Hu Raj K. Maturi David Almeida Andres Emanuelli Stanford Taylor Katrina Mears John Pitcher III Sunil Gupta Arshad M.

4D Molecular Therapeutics — Technical Presentation (July 2025) on 6ix